Rare Cancers: Health Services
(asked on 5th February 2026) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the commitment to explore novel procurement routes for diagnostics or treatments for rarer cancers contained in the 2026 National Cancer Plan includes assessing the suitability of the current approach to marketing authorisation in respect of treatments for rare and less common cancer.
Improving survival for rare cancer patients is a priority for the National Cancer Plan. The plan aims for England to climb into the top quartile in Europe for survival of multiple less common cancers by 2035.
We will explore which innovative procurement mechanisms, including advanced market commitments or advanced purchase agreements, could stimulate innovation for rarer cancers.
The Medicines and Healthcare products Regulatory Agency (MHRA) has completed a public consultation on its draft guideline on individualised mRNA cancer immunotherapies, a new type of personalised cancer treatment. These technologies use cutting-edge science such as artificial intelligence to design a medicine tailored to each patient’s unique tumour profile. The MHRA’s public consultation on its draft guideline on individualised mRNA cancer immunotherapies is available at the following link:
The MHRA will refine the guideline to ensure regulatory expectations are clearly articulated, without hampering innovation. This will facilitate faster access to these promising new therapies, while upholding our standards of safety, quality, and efficacy. The final version of the guideline will be published in the coming months, with future updates anticipated as regulatory experience evolves in this rapidly developing field.
To support measures that improve outcomes for rare cancer patients, the Government will implement the Rare Cancers Bill in full. The bill modernises how rare cancer drugs are approved, making sure our laws keep pace with other leading countries. It guarantees a new national specialty lead for rare cancers within the National Institute for Health and Care Research to drive research and leadership outcomes.